<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2918">
  <stage>Registered</stage>
  <submitdate>9/08/2010</submitdate>
  <approvaldate>9/08/2010</approvaldate>
  <nctid>NCT01203085</nctid>
  <trial_identification>
    <studytitle>Development of Charcot Marie Tooth Disease (CMT) Pediatric Scale for Children With CMT</studytitle>
    <scientifictitle>Development and Validation of CMT Pediatric Scale for Children With Charcot Marie Tooth</scientifictitle>
    <utrn />
    <trialacronym>INC-6603</trialacronym>
    <secondaryid>1U54NS065712-01</secondaryid>
    <secondaryid>INC-6603</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Charcot Marie Tooth Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Musculoskeletal</conditioncode1>
      <conditioncode2>Other muscular and skeletal disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Pediatric patients - All patients 21 years of age and under who are enrolled in the 6601 study and have undergone the pediatric scale tests.

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>CMT Peds Scale Part 1: Symptoms - The CMT Peds Scale Symptoms include foot and hand symptoms.</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CMT Peds Score Part 2: Foot and Ankle Involvement - Foot and ankle involvement includes foot posture index, range of ankle dorsiflexion, foot drop present/absent, and whether or not difficulty heel/toe walking.</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CMT Peds Scale Part 3: Hand dexterity - Hand dexterity involves hand dexterity testing and the nine-hole peg test.</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CMT Peds Scale Part 4: Hand strength - Hand strength includes grip strength, thumb-index pinch, and three point pinch.</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CMT Peds Scale Part 5: Foot Strength - Foot strength includes the strength of plantar- and dorsi-flexion, eversion, and inversion.</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CMT Peds Score Part 6: Sensation - Sensation includes pinprick and vibration sensations.</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CMT Peds Scale Part 7: Balance - Balance is assessed by the Bruininks-Oseretsky Test of Motor Proficiency, 2nd Edition (BOT-2).</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CMT Peds Scale Part 8: Motor Function - Motor function assessment includes long jump, 10 meter run/walk, stair climb, stair descend, and 6 minute walk test.</outcome>
      <timepoint>1 year</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate CMT Pediatric Scale (CMT Peds Scale) in CMT natural history study - The sections of the CMT Peds Scale which are found to be clinically/functionally useful after one year of analysis will be carried forward for all pediatric patients every 6 months to one year.</outcome>
      <timepoint>6 months to 1 year</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All patients MUST be seen in person at one of the participating centers for enrollment in
        this study.

          -  Children (&lt; 21 years of age)

          -  Known or probable inherited neuropathies classified as CMT1, CMT2, or CMT4</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>21</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Known diagnoses of acquired neuropathy including toxic (e. g. medication related
             neuropathies); metabolic (e.g. diabetic), immune mediated or inflammatory [acute
             inflammatory demyelinating polyradiculoneuropathy (AIDP) or chronic inflammatory
             demyelinating polyneuropathy (CIDP)] polyneuropathies; neuropathy related to
             leukodystrophy, congenital muscular dystrophy; and patients with severe general
             medical conditions.

          -  Entirely normal conduction velocities of upper and lower limbs as this suggests that
             the subject may not have a neuropathy.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Prospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/04/2010</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>500</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Children's Hospital of Westmead - Sydney</hospital>
    <postcode>2145 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>England</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>UK</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>University of Iowa</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Institute of Neurological Disorders and Stroke (NINDS)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Muscular Dystrophy Association</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University of Rochester</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Children's Hospital of Philadelphia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>University College London Hospitals</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Sydney Children's Hospitals Network</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Nemours Children's Clinic</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary goal of this project is to develop and test a Charcot Marie Tooth disease (CMT)
      Pediatric Scale for use in evaluation in natural history CMT study.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01203085</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Michael E Shy, MD</name>
      <address>University of Iowa</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Shawna M Feely, MS</name>
      <address />
      <phone>319-384-6362</phone>
      <fax />
      <email>Shawna-Feely@uiowa.edu</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>